Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data

June 1, 2026 9:59 AM EDT

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $30.00 price target on Immuneering Corporation (NASDAQ: IMRX) after the company reported 17.3-month survival data for pancreatic cancer drug/

The analyst commented, "Following RVMD's presentation of details from the RASolute-302 study during a plenary session at... More